FindTrial
Sign In

The Outcomes of Convalescent Plasma Therapy in Severe COVID-19 Patients Compared with Standard of Care; a Case-control Study

The Outcomes of Convalescent Plasma Therapy in Severe COVID-19 Patients Compared with Standard of Care; a Case-control Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20220101003
Enrollment
100
Registered
2022-01-01
Start date
2021-06-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus disease 2019 (COVID-19) causes severe pneumonia, respiratory failure, and high mortality. The COVID-19 convalescent plasma therapy (CPT) with a high titer of neutralizing antibodies is needed to prove the benefit in reducing mortality. COVID-19, convalescent plasma, severe COVID-19, Mortality

Interventions

Covid-19 Convalescent Therapy group,no recieved CPT group
Treatment,Treatment
CPT group,control group

Sponsors

Center of Learning and Research in Celebration of HRH Princess Chulabhorn 60th Birthday Anniversary
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 100 Years

Inclusion criteria

Inclusion criteria: 107 cases compatible with severe COVID-19 definition

Exclusion criteria

Exclusion criteria: Excluded 1,261 of mild cases -Excluded 1,260 of moderate cases -Exclude 40 of severe cases

Design outcomes

Primary

MeasureTime frame
CPT study could decrease mortality rate 85% 14-days mortality questionnaire—

Secondary

MeasureTime frame
The WHO clinical progression scale WHO clinical progression scale on day 0,3,5,14, after admission questionnaire—

Countries

Thailand

Contacts

Public ContactTaweegrit Siripongboonsitti

Chulabhorn Hospital

taweegrit.sir@pccms.ac.th0816924872

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026